Neonatal BCG-vaccination has no effect on recurrent wheeze in the first year of life. A randomized clinical trial
Abstract Background Recurrent wheeze is frequent in childhood. Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may have non-specific effects, reducing general non-tuberculosis morbidity, including respiratory infections and atopic diseases. The mechanisms behind these non-spec...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 2017-12, Vol.140 (6), p.1616-1621.e3 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract Background Recurrent wheeze is frequent in childhood. Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may have non-specific effects, reducing general non-tuberculosis morbidity, including respiratory infections and atopic diseases. The mechanisms behind these non-specific effects of BCG are not fully understood, but a shift from Th2 to Th1-response has been suggested as a possible explanation. Objective We hypothesized that BCG at birth would reduce the cumulative incidence of recurrent wheeze during the first year of life. Methods The Danish Calmette Study is a multicenter randomized trial conducted from 2012-2015 at three Danish hospitals. The 4262 newborns of 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control group within 7 days of birth; siblings were randomized together as one randomization unit. Exclusion criteria were gestational age |
---|---|
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/j.jaci.2016.12.990 |